Hansoh Pharmaceutical Group Co Limited/ADR
HNPHYDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
HS-20093
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Gemcitabine combined with docetaxel
Osteosarcoma
HS-20089
Ovarian Cancer
HS-10380 Low Dose
SCHIZOPHRENIA 1 (Disorder)
HS-20094
Overweight and Obesity
HS-10542
Paroxysmal Nocturnal Hemoglobinuria
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HS-20093 | Phase 3 | Metastasis Castration Resistant Prostate Cancer(mCRPC) | - | - |
Gemcitabine combined with docetaxel | Phase 3 | Osteosarcoma | - | - |
HS-20089 | Phase 2 | Ovarian Cancer | - | - |
HS-10380 Low Dose | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
HS-20094 | Phase 2 | Overweight and Obesity | - | - |
HS-10542 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hansoh Pharmaceutical Group Co Limited/ADR's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Hansoh Pharmaceutical Group Co Limited/ADR's (HNPHY) pipeline across Phase 3, Phase 2. Its lead program is HS-20093 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hansoh Pharmaceutical Group Co Limited/ADR's next FDA catalyst?→
Hansoh Pharmaceutical Group Co Limited/ADR's (HNPHY) next tracked catalyst is a Phase 2 expected May 30, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HNPHY biotech catalysts?→
Add HNPHY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hansoh Pharmaceutical Group Co Limited/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.